Welcome to our dedicated page for Heartflow news (Ticker: HTFL), a resource for investors and traders seeking the latest updates and insights on Heartflow stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heartflow's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heartflow's position in the market.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has successfully completed its upsized Initial Public Offering (IPO). The company sold 19,166,667 shares at $19 per share, including the full exercise of the underwriters' option to purchase additional 2,500,000 shares.
The IPO generated total gross proceeds of approximately $364.2 million before deducting underwriting discounts and other expenses. Trading of Heartflow's common stock began on the Nasdaq Global Select Market on August 8, 2025. The offering was jointly managed by J.P. Morgan, Morgan Stanley, and Piper Sandler, with Stifel and Canaccord Genuity acting as co-managers.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NYSE:HTFL) announced that UnitedHealthcare, the largest commercial insurer in the United States, will provide nationwide coverage for its AI-enabled Heartflow Plaque Analysis across all business lines. The coverage, effective October 1, 2025, will include Commercial, Medicare Advantage, and Community plans.
The FDA-cleared technology, showing 95% agreement with gold standard IVUS, helps diagnose and manage coronary artery disease (CAD). Clinical outcomes from the DECIDE registry demonstrated that management changes guided by Heartflow Plaque Analysis resulted in an average LDL cholesterol decrease of 18.7mg/dL, associated with a 15% reduction in cardiac event risk.
FAQ
What is the current stock price of Heartflow (HTFL)?
What is the market cap of Heartflow (HTFL)?
